Source: International Congress 2016 – Treatment options for obstructive sleep apnoea and obesity hypoventilation
Disease area: Sleep and breathing disorders

Abstract

Background: Obstructive sleep apnea syndrome (OSAS) is a disease with metabolic consequences and is associated with decreased levels of insulin-like growth factor-1 (IGF-1).Aim: To investigate whether continuous positive airway pressure (CPAP) increase IGF-1 in patients with OSAS.Methods: Consecutive patients with OSAS were recruited from a sleep clinic and IGF-1 was measured before initiation of CPAP and at follow-up after 4.8±2.4 months. Patients compliant to CPAP treatment (usage >4 hours/night) were compared with those considered to be non-compliant (usage <4 hours/night).Results: Complete data were obtained from 70 subjects (men 85.7%, age 55.8±11.9 years, apnea-hypopnea index (AHI) 42.5±21.1, Epworth sleepiness scale (ESS) 12.2±4.5). In those compliant to CPAP (n=41), there was an increase in IGF-1 with 22.1±25.3 ng/ml compared to 2.3±23.4 ng/ml in the non-compliant group (n=29) (P=0.0014). In multivariate analysis adjusting for gender, age, body mass index (BMI), average saturation during the night recording and AHI, there was a correlation between an increase in IGF-1 levels and compliance to CPAP (b-coefficient 27.4; 95% CI: 15.4-39.4), change in BMI (b-coefficient -6.8; 95% CI: -11.1- -2.6) and change in HbA1c (b-coefficient -1.7; 95 CI: -3.3- -0.06).Conclusion: CPAP >4 hours/night increases serum levels of IGF-1 in patients with OSAS.


Rating:

Share or cite this content

Citations should be made in the following way:
Andreas Palm (Gavle, Sweden), Andreas Palm, Christian Berne, Helena Igelström, Pernilla Åsenlöv, Christer Janson, Eva Lindberg. The impact of CPAP on circulating IGF-1 in patients with OSAS. Eur Respir J 2016; 48: Suppl. 60, 3421

Member's Comments

No comment yet.

Related content which might interest you: Patterns of CPAP usage in patients with minimally symptomatic OSA Source: International Congress 2015 – To treat or not to treat? Sleep-disordered breathing II Year: 2015 Weight changes in patients with obstructive sleep apnoea syndrome (OSAS) before and after CPAP Source: International Congress 2014 – Sleep disordered breathing: from children to the elderly Year: 2014 Increased circulating fibrocytes in asthmatic patients with severe OSA Source: International Congress 2016 – What's new in biomarker analysis? Year: 2016 The effect of CPAP on blood pressure in patients with OSAS and resistant hypertension followed 1 year Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Is there a relationship between OSAS severity and Nesfatin-1? Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 The positive effect of CPAP therapy on the level of liver enzymes in obstructive sleep apnea patients Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Prevalence of sleep apnea syndrome in morbidly obese patients Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing Year: 2013 Impact of CPAP treatment on pro-BNP in obstructive sleep apnea syndrome Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Long term effects of compliance with positive airway pressure (PAP) therapy in patients with obesity hypoventilation syndrome (OHS) Source: International Congress 2016 – Treatment options for obstructive sleep apnoea and obesity hypoventilation Year: 2016 Impact of septoplasty in the severity and treatment of sleep apnea Source: Annual Congress 2013 –Have we advanced in the treatment of sleep disordered breathing? Year: 2013 Sleep and sleep disordered breathing in a cohort of pre-LTX patients Source: International Congress 2016 – Effect of sleep apnoea on life-span and comorbidities Year: 2016 Improved adherence to CPAP by telemetric support in newly diagnosed OSAS patients Source: Annual Congress 2013 –Ask, see and do: old and new technology in sleep disordered breathing Year: 2013 Impacts of long-term CPAP therapy on fatty liver in male OSA patients with abdominal obesity Source: International Congress 2014 – Real or not? The impact of OSA and CPAP on comorbid conditions Year: 2014 C reactive protein and obstructive sleep apnea in obese patients Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Dietary treatment outcomes of mild obstructive sleep apnea in obese community-dwelling children: The NANOS study Source: International Congress 2015 – To treat or not to treat? Sleep-disordered breathing II Year: 2015 Resting energy expenditure among patients with obstructive sleep apnea syndrome: The impact of a single CPAP application Source: International Congress 2015 – Monitoring sleep-disordered breathing in children and adults Year: 2015 Daytime sleepiness in patients with obstructive sleep apnoea syndrome and its correlation to insulin resistance Source: International Congress 2016 – Effect of sleep apnoea on life-span and comorbidities Year: 2016 Sleep apnea in acromegaly Source: Annual Congress 2013 –Sleep disordered breathing in special situations III Year: 2013 Obesity and obstructive sleep apnea in children less than eight Years of age Source: Annual Congress 2013 –Assessing sleep disordered breathing and lung function in children Year: 2013 Nocturia is an independent predictive factor of prevalent hypertension in obstructive sleep apnea patients Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014